Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOHO-02 sevabertinib versus standard of care in first-line HER2-mutant advanced non-small cell lung cancer
2024-511319-91-00Phase 3Authorised
- Sponsor
- Bayer
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 35
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Sevabertinib with Standard of care (2 arms). Primary endpoint: Progression-free survival. Planned start Oct 2024; status: authorised.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-511319-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511319-91-00.